Additionally, the growth suppression imparted by Orlistat in HCC4006GR, H820, and H1650 cells carrying mutated EGFR strongly suggests that FASN is a valid target in TKI‐resistant EGFR mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.